Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
Key Points
Key Points
- Multiple studies of both chemotherapy and endocrine therapy have shown that neoadjuvant treatment can increase the likelihood of breast-conserving surgery.
- The CTNeoBC pooled analysis of neoadjuvant breast cancer clinical trials published in 2014 confirmed that achievement of a pathologic complete response (pCR) with neoadjuvant treatment was prognostic.
- It also showed that the association between pCR and outcomes was strongest in patients with triple negative and human epidermal growth factor receptor 2 (HER2)-positive disease.
- Optimal therapy for breast cancer is driven by subtype.
Treatment
Treatm...
...ation from 2022 Guideline Rapid Recommendation Upd...
...ith T1cN1-2 or T2-4N0 (stage II or III), early-...
...andidat...
...emotherapy is the treatment of choice for pa...
...stology, grade, stage and estrogen, proge...
...t systemic therapy should be offered...
...systemic therapy may be offered to...
...r whom a delay in surgery is preferable (e.g...
Measuring Response
...uring Respon...
...atients receiving neoadjuvant therapy should be mo...
...lood- and tissue-based biomarkers sho...
...absence of invasive disease in breast and lymph...
Recommended Regimens for Patients with TNBC
...ded Regimens for Patients with TNBC
...TNBC who have clinically node positiv...
...cT1a or cT1bN0 TNBC should not routinely be...
...may be offered as part of a neoadju...
...sufficient evidence to recommend r...
Recommended Neoadjuvant Treatment for Patients with HER2-negative/HR-positive Breast Cancer
...ed Neoadjuvant Treatment for Patients with HER2-...
...djuvant chemotherapy can be used in...
For postmenopausal patients with HR+,...
...remenopausal patients with HR+, HER2-ne...
Recommended Neoadjuvant Treatment for Patients with HER2-Positive Disease
...nded Neoadjuvant Treatment for Patients with...
Patients with node-positive or high-risk node-nega...
...atients with T1a N0 and T1b N0, HER2+ dise...